Proteomic analysis of S-nitrosylation induced by 1-methyl-4-phenylpyridinium (MPP+) by Akira T Komatsubara et al.
Komatsubara et al. Proteome Science 2012, 10:74
http://www.proteomesci.com/content/10/1/74RESEARCH Open AccessProteomic analysis of S-nitrosylation induced by
1-methyl-4-phenylpyridinium (MPP+)
Akira T Komatsubara1,2†, Tomoya Asano3†, Hiroki Tsumoto4, Kazuharu Shimizu4,5, Takumi Nishiuchi3,
Masanori Yoshizumi1 and Kentaro Ozawa1,4*†Abstract
Background: Nitric oxide (NO) mediates its function through the direct modification of various cellular targets.
S-nitrosylation is a post-translational modification of cysteine residues by NO that regulates protein function.
Recently, an imbalance of S-nitrosylation has also been linked to neurodegeneration through the impairment of
pro-survival proteins by S-nitrosylation.
Results: In the present study, we used two-dimensional gel electrophoresis in conjunction with the modified
biotin switch assay for protein S-nitrosothiols using resin-assisted capture (SNO-RAC) to identify proteins that
are S-nitrosylated more intensively in neuroblastoma cells treated with a mitochondrial complex I inhibitor,
1-methyl-4-phenylpyridinium (MPP+). We identified 14 proteins for which S-nitrosylation was upregulated and
seven proteins for which it was downregulated in MPP+-treated neuroblastoma cells. Immunoblot analysis
following SNO-RAC confirmed a large increase in the S-nitrosylation of esterase D (ESD), serine-threonine kinase
receptor-associated protein (STRAP) and T-complex protein 1 subunit γ (TCP-1 γ) in MPP+-treated neuroblastoma
cells, whereas S-nitrosylation of thioredoxin domain-containing protein 5 precursor (ERp46) was decreased.
Conclusions: These results suggest that S-nitrosylation resulting from mitochondrial dysfunction can compromise
neuronal survival through altering multiple signal transduction pathways and might be a potential therapeutic
target for neurodegenerative diseases.Background
Neurodegenerative diseases, including Parkinson’s, Alzheimer’s
and Huntington’s disease, occur as a result of the progres-
sive loss of the structure or function of neurons, including
the death of neurons. The exact mechanism of neuronal
cell death in neurodegeneration is not fully understood,
but it is usually accompanied by protein aggregation [1,2]
and increased indices of oxidative stress [3].
S-nitrosylation is the post-translational modification
(PTM) of the thiol group of a cysteine residue by nitric
oxide (NO). Recently, this process has been receiving
much attention as a mechanism by which NO ubiqui-
tously influences cellular signal transduction, including
neurodegeneration [4]. Recent studies have suggested* Correspondence: ko12@naramed-u.ac.jp
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distribution, and reproduction in any mediumthat nitrosative stress due to the generation of excessive
NO can mediate excitotoxicity in part by triggering pro-
tein misfolding and aggregation via the S-nitrosylation
of protein disulfide isomerase (PDI) or the E3 ubiquitin
ligase parkin [5]. S-nitrosylation of PDI inhibits the ac-
tivity of this enzyme, which leads to the accumulation of
misfolded proteins, activation of the unfolded protein re-
sponse, and neuronal cell death triggered by protein
misfolding and aggregation [6]. Parkin, mutation of
which causes a form of autosomal recessive juvenile
Parkinson disease, was also reported to be S-nitrosylated
and S-nitrosylation inhibits the E3 ubiquitin ligase activ-
ity and protective function of this protein [7].
S-nitrosylation is also involved in oxidative stress pro-
duced by mitochondria, which can subsequently induce
neurodegeneration [3]. One of the major sources of
oxidative stress in cells is the process of oxidative
phosphorylation in the mitochondria, and NO can mediate
excitotoxicity in part by triggering mitochondrial fragmen-entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 S-nitrosylation of parkin, β-arrestin 2, and GAPDH in
neuroblastoma cells treated with MPP+. Parkin (A) or β-arrestin 2
(B) were overexpressed in SH-SY5Y cells. The SH-SY5Y cells were then
treated with MPP+ (100 μM) for 3 h, and lysates prepared from the
treated cells were analyzed by the SNO-RAC assay, in which ascorbate-
dependent capture of proteins by resin indicates the presence of S-
nitrosylated cysteine residues. Elutants were subjected to immunoblot
analysis using anti-FLAG (A, B) or anti-GAPDH (C) antibody.
Komatsubara et al. Proteome Science 2012, 10:74 Page 2 of 7
http://www.proteomesci.com/content/10/1/74S-nitrosylation of the mitochondrial fission protein
dynamin-related protein 1 (Drp1) is activated by amyloid-β
peptide, which is a key mediator of the pathogenesis of
Alzheimer’s disease. The resulting hyperactivation of Drp1
leads to excessive mitochondrial fragmentation, the pro-
duction of oxidative stress, and neuronal cell death [8].
In different neurodegenerative disorders, the abnormal
programmed cell death of neurons has been suggested
to be one of the major causes of the degeneration, and the
S-nitrosylation of glyceraldehyde 3-phosphate dehydrogen-
ase (GAPDH) triggers cell death in many types of cell [9].
GAPDH catalyzes the sixth step of glycolysis and thus
serves to break down glucose for energy and carbon mole-
cules. However, over the years, there have been reports
that GAPDH is implicated in several non-metabolic pro-
cesses, including the initiation of apoptosis. NO causes the
S-nitrosylation of GAPDH, followed by translocating the
complex of GAPDH and the E3 ubiquitin ligase Siah to
the nucleus and subsequent cell death [9,10].
In the present study, to investigate the effects of S-nitro-
sylation on protein function under conditions of mitochon-
drial dysfunction, we analyzed the level of S-nitrosylated
proteins in the neuroblastoma cell line SH-SY5Y after ex-
posure to the mitochondrial complex I inhibitor 1-methyl-
4-phenylpyridinium (MPP+). Using the two-dimensional
electrophoresis (2DE) technique, we identified several pro-
tein spots for which the intensity was increased by expos-
ure to MPP+. We then evaluated the S-nitrosylation of
several proteins that were identified by immunoblotting
after separation by the modified biotin switch assay for pro-
tein S-nitrosothiols using resin-assisted capture (SNO-
RAC) [11].
Results and discussion
Purification of S-nitrosylated proteins by SNO-RAC
S-nitrosylation plays important roles in modifying the
function of proteins under physiological and patho-
physiological conditions [4], and accurate quantification
of the extent of S-nitrosylation at a particular cysteine
residue is essential to understand its influence on signal
transduction. One method used for quantification is the
biotin-switch technique (BST), in which S-nitrosylated
cysteines are converted into more stable biotinylated
forms [12]. The BST method involves three steps: 1) free
cysteine thiols are blocked with S-methylmethanethio-
sulfonate, 2) nitrosylated cysteines are reduced by as-
corbate without the concomitant reduction of disulfide
bonds or other oxidative cysteine PTMs, and 3) newly-
exposed cysteine thiols are alkylated classically by
biotin-HPDP. However, other techniques, such as SNO-
RAC, have also been employed to good effect [11].
We tested that MPP+ enhances S-nitrosylation nonspe-
cifically or not by evaluating levels of S-nitrosylated
proteins which have been reported, Parkin, β-arrestin 2and GAPDH. Parkin [7] and GAPDH [9] were reported to
be S-nitrosylated more potently under MPP+-treatment,
whereas S-nitrosylation of β-arrestin 2 is increased by the
activation of GPCR and denitrosylated rapidly [13]. To
detect S-nitrosylated parkin or β-arrestin 2, parkin and β-
arrestin 2 were overexpressed separately in SH-SY5Y cells.
After the cells had been treated with MPP+ for 3 h, we puri-
fied the S-nitrosylated proteins by SNO-RAC from cell
extracts that had been prepared. Then we performed
immunoblot analysis using anti-FLAG (to detect overex-
pressed parkin (Figure 1A) or β-arrestin 2 (Figure 1B) and
anti-GAPDH (Figure 1C) antibodies, respectively. Consist-
ent with previous studies, the level of S-nitrosylated parkin
was increased in MPP+-treated cells as compared with con-
trol cells. In contrast, the levels of S-nitrosylated β-arrestin
2 and GAPDH were not altered. S-nitrosylation of GAPDH
was reported to be up-regulated in brain tissues exposed to
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [14],
which is metabolized into MPP+ in brain tissue, which sug-
gests that the overexpression of inducible NO synthase
(iNOS) as a result of inflammation might contribute signifi-
cantly to S-nitrosylation of GAPDH in brain tissues trea-
ted with MPTP. On the other hand, Chung et al.
reported Parkin was S-nitrosylated in brain tissue of
iNOS knockout mice treated with MPTP [7], suggesting
nNOS contribute to S-nitrosylation of Parkin induced
by MPTP. The results obtained in the present study
showed that treatment with MPP+ does not upregulate
the S-nitrosylation of all proteins.
Proteomic analysis of S-nitrosylated proteins in SH-SY5Y cells
To investigate the roles of S-nitrosylation in MPP+-treated
neuroblastoma cells, we performed 2DE as described in the
Materials and Methods. From the 2DE, we identified sev-
eral protein spots for which the levels differed between
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(Figure 2A, B, C and D). The spots were picked, and the
proteins in the picked gel plugs were digested in gel with
trypsin and prepared for mass spectrometry analysis as
described in the Materials and Methods.
Fourteen proteins were identified from 14 spots of which
the signals increased in MPP+-treated cells, whereas an-
other set of seven proteins were identified from seven spots
of which the signals decreased in MPP+-treated cells.
These upregulated and downregulated S-nitrosylated pro-
teins are listed in Tables 1 and 2, respectively, together with
their accession number, signal-ratio (MPP+-treated/con-
trol), name, calculated molecular weight, calculated pI, the
ProtScore and sequence coverage. We also analyzed the
results of mass spectrometry using Scaffold version 3.0
(Proteome Software, Portland, OR) and found that S-
nitrosylation of proteins belonging to a wide range of func-
tional categories was altered in samples from MPP+-treated
cells (Figure 2E and F).
Our results suggested S-nitrosylation might play an
important role in DNA repair. MPP+-treatment enhan-
ced S-nitrosylation of proliferating cell nuclear antigenFigure 2 2D-gel electrophoresis and categorization of the proteins. R
extracts of control (A) and MPP + -treated cells (B). High-magnification i
(C) and MPP+-treated cells (D). Number represents ID of each spot. The
processes (E), and 6 cellular localization sites (F).(PCNA), which plays an important role in several DNA
damage-responsive pathways as well as DNA replication
[15]. In additon, PCNA was reported to be associated
with Parkin [16], suggesting S-nitrosylation of PCNA
might involve the regulation of DNA repair caused by
mitochondrial dysfunction. Furthermore, MPP+-treatment
enhanced S-nitrosylation of STRAP, which activates p53
by removing Mdm2, a negative regulator of p53 [17], sug-
gesting S-nitrosylation of STRAP might regulate DNA re-
pair through the activation of p53.
S-nitrosylation of the α- and β-subunit of tubulin,
which have been reported to be S-nitrosylated previously
[12], was upregulated in MPP+-treated neuroblastoma
cells, which suggested that our experiment detected S-
nitrosylated proteins. In a previous report, S-nitrosylation
of the α- and β-subunit of tubulin was shown to regulate
their polymerization by regulating the formation of inter-
and intramolecular disulfide bonds [18].
Detection of S-nitrosylated proteins in SH-SY5Y cells
To confirm the results of the 2DE, S-nitrosylation of ester-
ase D (ESD), serine-threonine kinase receptor-associatedepresentative 2D images of S-nitrosylated proteins in the cell
mages of S-nitrosylated proteins in the cell extracts of control
differentially expressed proteins can be classified into 7 biological







pI ProtScore (a) % Cov (b)
1 TM11E_HUMAN 1.78 Transmembrane protease, serine 11E precursor
/DESC1
47.7 8.85 1.4 5.2
TBA6_HUMAN Tubulin alpha-6 chain 49.9 4.96 12 16.7
2 TM11E_HUMAN 2.15 Transmembrane protease, serine 11E precursor
/DESC1
47.7 8.85 1.7 4
3 TM11E_HUMAN 1.85 Transmembrane protease, serine 11E precursor
/DESC1
47.7 8.85 0.7 3.3
4 TM11E_HUMAN 1.82 Transmembrane protease, serine 11E precursor
/DESC1
47.7 8.85 0.64 3.3
TNF10_HUMAN Tumor necrosis factor ligand superfamily
member 10
32.5 7.01 1.05 5.3
5 TBB2C_HUMAN 1.92 Tubulin beta-2C chain 49.8 4.79 15.74 23.4
TBB5_HUMAN Tubulin beta chain 49.7 4.78 15.74 23.4
6 RSSA_HUMAN 3.45 40S ribosomal protein SA/Laminin receptor 32.9 4.79 6 18
7 PCNA_HUMAN 1.51 Proliferating cell nuclear antigen (PCNA) 28.8 4.57 10 32.6
8 STRAP_HUMAN 2.14 Serine-threonine kinase receptor-associated
protein
38.4 4.98 2 2.9
9 TCPG_HUMAN 2.45 T-complex protein 1 subunit gamma 60.5 6.1 14.22 22
10 GBLP_HUMAN 1.69 Guanine nucleotide-binding protein subunit
beta 2-like 1
35.1 7.6 2 1.2
11 ESTD_HUMAN 2.15 S-formylglutathione hydrolase/Esterase D 31.5 6.54 9.7 25.5
12 KNG1_HUMAN 3.87 kininogen-1 precursor 72 6.34 2 1.2
13 TXND5_HUMAN 1.52 Thioredoxin domain-containing protein 5
precursor/ERp46
47.6 5.63 3.55 9.5
14 FIBB_HUMAN 2.45 Fibrinogen beta chain precursor 55.9 8.54 2 2.9
a. The Total ProtScore is a measure of the total amount of evidence for a detected protein, which was calculated using all of the peptides detected for the
protein.
b. % Sequence coverage.
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1 γ), and thioredoxin domain-containing protein 5 precur-
sor (ERp46) were analyzed. ESD, which is also known as S-
formylglutathione hydrolase (FGH), constitutes part of a
formaldehyde detoxification pathway by catalyzing the hy-
drolysis of S-formylglutathione to formic acid and glutathi-
one [19]. ESD was first purified from human tissues, in






15 GANAB_HUMAN 0.57 Neutral alpha-glucosida
16 PRD13_HUMAN 0.65 PR domain zinc finger p
17 ROA2_HUMAN 0.58 Heterogeneous nuclear
A2/B1
18 ACTG_HUMAN 0.66 Actin, cytoplasmic 2
19 EF1G_HUMAN 0.46 Elongation factor 1-gam
20 EF2_HUMAN 0.59 Elongation factor 2
21 FHL1_HUMAN 0.64 Four and a half LIM do
a. The Total ProtScore is a measure of the total amount of evidence for a detected
protein.
b. % Sequence coverage.with several diseases, including retinoblastoma [20] and
Wilson’s disease [21]. STRAP is a transforming growth
factor-β (TGF-β) receptor-interacting protein that inhibits
TGF-β signaling by stabilizing the association between
TGF-β receptors and SMAD7 [22,23]. TCP-1 γ is a mo-
lecular chaperone that is a member of the chaperonin-
containing TCP1 complex (CCT), which is also known as
the TCP1 ring complex (TRiC) [24]. ERp46 has a PDIted cells compared with control
ME Mass
(kDa)
pI ProtScore (a) % Cov (b)
se AB precursor 106.9 5.74 4.25 6.1
rotein 13 74 9 2.01 4.2
ribonucleoproteins 36 8.67 3.71 10.8
41.8 5.31 24 38.7
ma 50.1 6.25 16.74 23.6
95.3 6.41 18.45 25.8
main protein 1 36.3 9.25 15.7 23.5
protein, which was calculated using all of the peptides detected for the
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doxin, which catalyzes the rate limiting reaction of disul-
phide bond formation, isomerization, and reduction [25].
We amplified and subcloned cDNA for ESD, STRAP,
TCP-1 γ, and ERp46 with a FLAG tag. Then we analyzed
cell extracts prepared from SH-SY5Y cells overexpres-
sing ESD, STRAP, TCP-1, and ERp46, respectively, by
SNO-RAC assay, followed by immunoblot analysis using
an anti-FLAG antibody (Figure 3). The samples that
were prepared in the absence of ascorbate showed neg-
ligible signals, which demonstrated that each protein
contained cysteine(s) that were reduced in an ascorbate-
dependent manner. The results of the assay showed that
ESD, STRAP, TCP-1, and ERp46 were S-nitrosylated in
SH-SY5Y cells in the absence of MPP+ treatment.
Furthermore, we evaluated levels of S-nitrosylated pro-
teins in cell extracts that had been prepared from MPP
+-treated (3 h) SH-SY5Y cells by the SNO-RAC assay.
Consistent with our 2DE experiment, treatment with MPP
+ increased the level of S-nitrosylation of ESD, STRAP,
and TCP-1, which indicated that our proteomics method
that combined SNO-RAC and 2DE successfully detected
proteins that show enhanced S-nitrosylation upon expos-
ure to MPP+ (Figure 4A, C and D). On the other hand,
S-nitrosylation of ERp46 was decreased by MPP+-treat-
ment (Figure 4B), possibly because of electrophoretic
mobility shift by other PTM(s) in ERp46 or existence
of protein(s) in the gel-plug.
Concluding remarks
In the present study, we used a combination of 2DE and
SNO-RAC to identify S-nitrosylated proteins that had
been modified more intensively than others upon expos-
ure to MPP+. We confirmed that ESD, STRAP andFigure 3 Detection of S-nitrosylated ESD, STRAP, TCP-1 γ, and
ERp46. ESD (A), STRAP (B), TCP-1 γ (C), and ERp46 (D) were
overexpressed in SH-SY5Y cells, and lysates prepared from the
treated cells were analyzed by the SNO-RAC assay, in which
ascorbate-dependent capture of proteins by resin indicates the
presence of S-nitrosylated cysteine residues. Elutants were subjected
to immunoblot analysis using anti-FLAG antibody.TCP-1 were S-nitrosylated markedly upon MPP+ treat-
ment, whereas S-nitrosylation of ERp46 decreased. Our
observations provided clear evidence that MPP+ treatment
changed the level of S-nitrosylation on several proteins,
which were involved in multiple signal transduction path-
ways. This suggests that the neurotoxicity of MPP+ is
effected through multiple pathways and S-nitrosylation
might play an important role in this process. It is likely
that application of the experimental approach described in
the present study in other cell and biological systems will
provide a more comprehensive understanding of the pre-




Sequencing-grade trypsin was purchased from Promega
(Madison, WI). The protease inhibitor cocktail was
obtained from Roche Applied Science (Switzerland). IPG
buffer was purchased from GE Healthcare, and ZipTipC18
columns from Millipore, respectively. Anti-FLAG mono-
clonal antibody and 1-methyl-4-phenylpyridinium was
obtained from Sigma-Aldrich (St. Louis, MO).
Transfection
Transfection of the expression constructs were performed
using lipofectamine LTX (Invitrogen).
Purification of S-nitrosylated proteins by SNO-RAC
S-nitrosylated proteins were purified by using SNO-RAC
[11] with some modifications. Briefly, SNO-RAC Resins
were prepared as described. Then, lysates (250 ml
diluted with 750 ml HEN buffer containing 250 mM
HEPES, 1 mM EDTA, 0.1 mM neocuproine [pH 8.0])Figure 4 S-nitrosylation of ESD, STRAP, TCP-1 γ, and ERp46 in
neuroblastoma cells treated with MPP+. ESD (A), STRAP (B), TCP-
1 γ (C), and ERp46 (D) were overexpressed in SH-SY5Y cells. The SH-
SY5Y cells were then treated with MPP+ (100 μM) for 3 h, and
lysates prepared from the treated cells were analyzed by the SNO-
RAC assay, in which ascorbate-dependent capture of proteins by
resin indicates the presence of S-nitrosylated cysteine residues.
Elutants were subjected to immunoblot analysis using anti-FLAG
antibody.
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methyl methanethiosulfonate (Sigma-Aldrich; St. Louis,
MO) at 50°C for 25 min. Proteins were precipitated with
acetone, washed three times, resuspended in HENS buf-
fer (HEN containing 1% SDS; 200 ml). This material is
added to 50 μl resin slurry in the presence of sodium as-
corbate (Fluka, final 20 mM). Following rotation in the
dark for 3 h, the resin was washed with 4 x 1 ml HENS
buffer. Captured proteins are eluted with 30 ml HENS
buffer containing 100 mM 2- mercaptoethanol for
20 min at RT, precipitated with acetone and resuspended
in sample buffer (4 M urea, 2%(w/v) CHAPS, 10 mg/ml
DTT and 1%(v/v) PharmalyteTM) .
Separation by 2D-gel electrophoresis
2DE was carried out as reported previously [26]. In brief,
for isoelectric focusing (IEF), samples were loaded onto
rehydration strips that were 18 cm in length with an
immobilized pH gradient from 3 to 10 and separated on
a MultiPhor Unit (GE Healthcare). After the first separ-
ation, the strips were equilibrated in equilibration buffer
A [50 mM Tris–HCl, pH 8.8, 6 M urea, 30% (v/v) gly-
cerol, 2% (w/v) SDS, 1% DTT, 0.002% (w/v) bromophe-
nol blue] and then in equilibration buffer B [50 mM
Tris–HCl, pH 8.8, 6 M urea, 30% (v/v) glycerol, 2% (w/
v) SDS, 2.5% iodoacetamide, 0.002% (w/v) bromophenol
blue] for 15 min. Separation in the second dimension
was achieved using a Hoefer SE 600 Ruby electrophor-
esis system (GE Healthcare) and 10% polyacrylamide
gels. After electrophoresis, gels were stained with Coo-
massie Brilliant Blue (Figure 1). The experiments were
performed twice and the similar images were obtained.
Quantitation analysis
After staining, gels were scanned and analyzed by ImageJ
(National Institutes of Health, Bethesda, MD) to de-
tect, subtract background of, normalize, and quantify
the spots in images from a single 2D-gel. Our quanti-
tation analysis revealed the signal intensities of 14
spots were ≥1.5-fold higher (i.e., increase in protein
expression) and signal intensities of 7 spots were 2/3-
fold lower (i.e., decrease in protein expression) in the
MPP+-treated sample compared to their respective
spots in the wild-type sample.
Identification of proteins
Proteins were identified as described previously [26]. MS/
MS analysis was performed with a 4800 plus MALDI TOF/
TOFTM Analyzer (ABsciex, California, USA), and proteins
were identified by using the ParagonTM algorithm [27] of the
Protein PilotTM software (ABsciex, California, USA). For
each protein identification, total ProtScore were used. The
total ProtScore is a measurement of all the peptide evi-
dence for a protein and is analogous to protein scoresreported by other protein identification software. Basically
proteins whose ProtScores were higher than 1.0 were listed
in Tables 1 and 2, but Transmembrane protease, serine 11E
precursor/DESC1 with lower ProtScore was anomalistically
included in the Table 1 because DESC1 was identified from
several spots. Cellular localizations and biological processes
of proteins identified by MIS were categorized using
Scaffold version 3.0 (Proteome Software, Portland, OR).
Western blotting
Cell lysates were prepared using a Qproteome Mammalian
Protein Prep Kit (Qiagen, Germany). Samples were ana-
lyzed by western blotting. After transfer to PVDF mem-
branes, immunoreactive bands were visualized using the
enhanced chemiluminescence detection system and indi-
cated antibodies as described previously [28].
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